Genprex

Genprex, Inc. is a clinical-stage gene therapy company, which engages in the development of therapies for patients with cancer and diabetes. The company’s lead product candidate is REQORSA immunogene therapy drug for non-small cell lung cancer. Its other technologies include GPX-002 gene therapy for diabetes, and ONCOPREX nanoparticle delivery system. Genprex was founded by J. Rodney Varner in April 2009 and is headquartered in Austin, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AUSTIN, Texas--(BUSINESS WIRE)--Genprex announces participation in February conferences.

Genprex to Present at Upcoming Investor Conferences Highlighting its Gene Therapies for Cancer and Diabetes

Gatos Silver

Indonesia Energy Corp Ltd

Save Foods

4 names for your penny stocks list this week. The post 4 ‘Must Watch' Penny Stocks Making Big Moves After Latest News appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 ‘Must Watch' Penny Stocks Making Big Moves After Latest News

Genprex Inc announced that its collaborators published positive clinical data for the use of Genprex's ONCOPREX Nanoparticle Delivery System for delivery of a FAS DNA plasmid to treat metastatic colorectal cancer. Published in the journal Cancers, the preclinical study found that tumor-selective ONCOPREX nanoparticles carrying FAS DNA plasmids suppress human colon tumor growth in vivo in mouse models, indicating that this may be an effective therapy for human colorectal cancer.

Genprex says preclinical data shows potential for ONCOPREX Nanoparticle Delivery System in treating colon cancer

AUSTIN, Texas--(BUSINESS WIRE)--Preclinical data finds that Genprex's ONCOPREX Nanoparticle Delivery System may be a potential platform for colon cancer

Preclinical Data Show Potential for Use of Genprex's ONCOPREX® Nanoparticle Delivery System in Treating Colon Cancer

Genprex Inc has announced a plan to accelerate the opening of trial sites for the Acclaim-1 clinical trial, which combines the company's lead product candidate, REQORSA (quaratusugene ozeplasmid) Immunogene Therapy, with AstraZeneca's Tagrisso as a potential innovative treatment for non-small cell lung cancer (NSCLC). The company said the opening of four clinical trial sites to enroll patients in the Phase 1 portion of Genprex's Acclaim-1 clinical trial is underway as part of a collaboration agreement with a large network of integrated, community-based oncology practices, with an expectation of opening additional sites in the Phase 2 portion of the study.

Genprex says it plans to ramp up opening of its Acclaim-1 clinical trial sites

AUSTIN, Texas--(BUSINESS WIRE)--Genprex announced a plan to accelerate the opening of clinical trial sites for the Acclaim-1 clinical trial.

Genprex to Accelerate Opening of Acclaim-1 Clinical Trial Sites for REQORSA™ Systemic Gene Therapy in Non-Small Cell Lung Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Genprex announces its conference participation for January 2022.

Genprex to Participate in January Investor and Healthcare Conferences to Highlight Company's Gene Therapies in Cancer and Diabetes

The FDA bestows a Fast Track designation to Genprex's (GNPX) Reqorsa in combination with Keytruda for treating patients with non-small cell lung cancer. This is the second Fast Track tag for Reqorsa.

Genprex's (GNPX) Lead Cancer Drug Gets Second Fast Track Tag

AUSTIN, Texas--(BUSINESS WIRE)--Genprex expands its clinical development pipeline to include Small Cell Lung Cancer.

Genprex Expands Gene Therapy Oncology Pipeline to Include Small Cell Lung Cancer

The stock price of Genprex Inc (NASDAQ: GNPX) increased by 167.18% in the most recent trading session. This is why it happened.

Genprex Stock (GNPX): Why The Price Surged

Genprex Inc (NASDAQ: GNPX) is a clinical-stage gene therapy organization that concentrates on the development of life-changing gene therapies to treat people with diabetes and cancer. The company announced that it had received FTD (Fast Track Designation) from the Food and Drug Administration for its REQORSA Immunogene therapy and went up by 130%.

Genprex up by 130% after receiving FDA fast track designation

Shares of Genprex Inc. GNPX, +121.37% skyrocketed 121% on massive volume in afternoon trading Monday, after the gene therapy company said its Reqorsa Immunogene Therapy was granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration for use in combination with Merck & Co. Inc.'s MRK, -0.29% cancer treatment Keytruda. Trading volume exploded to 163.9 million shares, compared with the full-day average of about 476,600 shares, and enough to make the stock the most actively traded on major U.S. exchanges.

Genprex stock more than doubles on very heavy volume after FTD granted for cancer treatment

Shares of GNPX stock are soaring higher after the FDA granted fast track designation (FTD) for the company's lead drug candidate, REQORSA. The post GNPX Stock: 5 Things to Know as Genprex Rockets Higher appeared first on InvestorPlace.

GNPX Stock: 5 Things to Know as Genprex Rockets Higher

Armstrong Flooring

Applied UV

BlueCity Holdings Limited

Creative Medical Technology Holdings

PolarityTE Inc

Eco Wave Power Global AB

We're diving into the top penny stocks to watch today as several names in the space see major movement on Monday alongside heavy trading. The post 8 Top Penny Stocks to Watch Today: EVGRF, PTE, BLCT, GNPX, AFI, CELZ, AUVI, WAVE appeared first on InvestorPlace.

8 Top Penny Stocks to Watch Today: EVGRF, PTE, BLCT, GNPX, AFI, CELZ, AUVI, WAVE

Genprex Inc (NASDAQ: GNPX) is trading higher Monday after the company announced it received U.S. Food and Drug Administration Fast Track Designation (FTD) for REQORSA Immunogene Therapy in combination with Merck & Co Inc's (NYSE: MRK) Keytruda for the treatment of non-small cell lung cancer. The FTD is for patients with histologically-confirmed unresectable stage 3 or 4 non-small cell lung cancer whose disease progressed after treatment with Keytruda.

Why Genprex Shares Are Soaring Today

Focused on developing life-changing therapies for patients with cancer and diabetes  Advancing lead product REQORSA immunogene therapy for non-small cell lung cancer Struck licensing agreement with the University of Pittsburgh for diabetes gene therapy What Genprex does: Genprex Inc (NASDAQ:GNPX) is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes.  The Austin, Texas company's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations who currently have limited treatment options.

Genprex targets non-small cell lung cancer and diabetes via gene therapy

Genprex, Inc. (NASDAQ:GNPX) revealed that the US Food and Drug Administration (FDA) granted Fast Track designation to the company's lead drug candidate, REQORSA Immunogene Therapy, in combination with Merck & Co Inc (NYSE:MRK)'s Keytruda in patients with stage III or IV non-small cell lung cancer (NSCLC), where disease progressed after treatment with Keytruda. The Austin, Texas-based clinical-stage gene therapy company said that in the first quarter of 2022, it plans to initiate its Acclaim-2 clinical trial, which is an open-label, multicenter Phase 1/2 clinical trial evaluating REQORSA in combination with Keytruda, for this patient population.

Genprex wins Fast Track designation for REQORSA in combo with Keytruda for treating Non-Small Cell Lung Cancer from FDA

The FDA has granted Fast Track Designation for Genprex Inc's (NASDAQ: GNPX) lead drug candidate, Reqorsa Immunogene combination therapy. The designation covers Reqorsa combined with Merck & Co Inc's (NYSE: MRK) Keytruda for unresectable stage III or IV non-small cell lung cancer (NSCLC) whose disease progressed after treatment with Keytruda.

Genprex's Lead Cancer Program Scores Second FDA Fast Track Tag For Lung Cancer Setting

AUSTIN, Texas--(BUSINESS WIRE)--Genprex Received FDA Fast Track Designation for REQORSA Immunogene Therapy in Combination with Keytruda for Non-Small Cell Lung Cancer

Genprex Receives U.S. FDA Fast Track Designation for REQORSA™ Immunogene Therapy in Combination With Keytruda® for the Treatment of Non-Small Cell Lung Cancer

GNPX is a clinical-stage biotech company developing gene therapies for the treatment of cancer and diabetes.

Genprex: Limited Clinical Data To Justify Risk

AUSTIN, Texas--(BUSINESS WIRE)--Genprex's CEO will present on November 17 at 11 a.m. ET with CEO Roadshow.

Genprex to Present in November CEO Roadshow Webinar

Greenpro Capital Corp

Moving Image Technologies

Synthetic Biologics

United States Antimony

Are these penny stocks on your Webull watch list? The post 5 Top Penny Stocks To Buy For Under $5 On Webull Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Top Penny Stocks To Buy For Under $5 On Webull Today

Genprex, Inc. said it has strengthened its leadership team with the appointments of Dr Mark S.

Genprex strengthens leadership team with appointments to newly-created positions of chief medical officer and of chief manufacturing and technology officer

AUSTIN, Texas--(BUSINESS WIRE)--Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Company has strengthened its leadership team with the appointments of Mark S. Berger, M.D. to the newly-created position of Chief Medical Officer and Hemant Kumar, Ph.D., CPM, EMBA to the newly-created position of Chief Manufacturing and Technology Officer. Dr

Genprex Strengthens Management Team with Appointments of Industry Leaders Mark S. Berger, M.D.

AUSTIN, Texas--(BUSINESS WIRE)--Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its President and Chief Executive Officer, Rodney Varner, will be participating in two investor conferences in September 2021. CEO Roadshow Webinar Format: Company presentation Presentation Date/Time: September 22, 2021 at 11:00 a.m. ET Access: https://bit.ly/3eoH

News for Genprex Stock (GNPX)